Thursday November 4, 8:04 am Eastern Time
Company Press Release
SOURCE: CompuMed, Inc.
CompuMed Announces Filing of U.S. Patents for Automated Osteogram(R) 2000
LOS ANGELES, Nov. 4 /PRNewswire/ -- CompuMed, Inc. (Nasdaq: CMPDC - news) announced today that two applications have been filed with the U.S. Patent Office for its OsteoGram® 2000 software. The pending patents deal with CompuMed's software detection using hand X-rays to determine bone mineral density.
''We are pleased to report the filing of two U.S. patents for the OsteoGram® 2000,'' stated Robert B. Goldberg, Chairman and CEO of CompuMed. ''In light of the beta sites recent feedback, CompuMed scientists and engineers have put together a detailed, systematic description of the Food and Drug Administration (FDA) approved software which has been submitted to the Patent Office. We look forward to the near future release of this advanced system that we believe will be the most cost effective and accurate osteoporosis diagnostic tool in the market.''
CompuMed, based in Los Angeles, California, develops solutions to important medical problems through the use of computer technology. In addition to the Automated OsteoGram® 2000 and the developmental Digital OsteoView 2000, CompuMed has developed computer-aided telemedicine services for cardiology and currently provides on-line computer interpretation of electrocardiograms to physicians, government, and corporate health care providers.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks defined in this document. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact: Robert B. Goldberg, Chairman and Chief Executive Officer of CompuMed, Inc., 310-258-5000, ext 115; or media - Kristen Hammer of Noonan/Russo Communications, Inc., 212-696-4455, ext 249, e-mail news@noonanrusso.com, for CompuMed, Inc.
SOURCE: CompuMed, Inc.
--------------------------------------------------------------------------------
More Quotes and News: Compumed Inc (NasdaqSC:CMPDC - news)
Related News Categories: computers, medical/pharmaceutical
-------------------------------------------------------------------------------- |
